(MENAFN- ProactiveInvestors)
() is increasing protection of its intellectual property with the lodgement of a provisional patent application with the U.S. Patent Office.
The application covers an objective test to measure the level of stress and its impact on health and wellbeing.
This will complement the existing patents covering mental health diagnosis held by Medibio.
Lodgement of this new patent is the first in Medibio’s IP strategy of creating and protecting a dominant and defensible position in the use of Circadian Heart Rate (CHR) technology in the areas of stress and mental health.
It specifically covers the use of CHR technology to assess the level and impact of stress.
More specifically it measures the type and degree of deviation of the subject’s CHR from normal and uses the diagnostic significance of this to accurately classify individuals into one of three categories based on the impact stress has had on their health and wellbeing.
The company is also advancing new patent applications covering new understanding obtained over the past 18 months specifically related to mental health diagnosis.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.